Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ:REGN)

605.39 +13.54 (+2.29%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 29, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 756,786
Open 597.06
Bid (Size) 597.00 (1)
Ask (Size) 605.39 (1)
Prev. Close 591.85
Today's Range 591.02 - 605.73
52wk Range 520.50 - 1,211.20
Shares Outstanding 91,779,465
Dividend Yield 0.15%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Itepekimab Met Primary Endpoint in One of Two Chronic Obstructive Pulmonary Disease (COPD) Phase 3 Trials
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
The Company Buying 23andMe Is a Pharmaceutical Giant. Here's How Investors Can Benefit From the Move.
Via The Motley Fool
Topics Artificial Intelligence Bankruptcy
Exposures Artificial Intelligence Financial Legal

Performance

YTD
-15.4%
-15.4%
1 Month
-0.9%
-0.9%
3 Month
-15.1%
-15.1%
6 Month
-19.2%
-19.2%
1 Year
-37.8%
-37.8%

More News

Read More
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
3 Value Stocks with Questionable Fundamentals
Via StockStory
Does the 23andMe Acquisition Make Regeneron a Buy Now?
Via The Motley Fool
Topics Bankruptcy
Exposures Financial Legal
Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 15 Years
Via Benzinga
Linvoseltamab in Combination with Carfilzomib or Bortezomib Shows Promising Initial Results in Earlier Lines of Treatment for Relapsed/Refractory Multiple Myeloma
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
3 Cash-Producing Stocks in Hot Water
Via StockStory
What's going on in today's session: S&P500 movers
Via Chartmill
Genetic Data From 23andMe Ends Up With This Company In $256 Million Deal
Via Benzinga
Regeneron To Buy Assets Of 23andMe For $256M: Retail Says ‘Fantastic’ For Future R&D Efforts
Via Stocktwits
Topics Artificial Intelligence Bankruptcy
Exposures Artificial Intelligence Financial Legal
23andMe Finds A Big Biotech Buyer In $256 Million Bankruptcy Auction
Via Investor's Business Daily
Topics Bankruptcy
Exposures Financial Legal
Regeneron Enters into Asset Purchase Agreement to Acquire 23andMe® for $256 Million; Plans to Maintain Consumer Genetics Business and Advance Shared Goals of Improving Human Health and Wellness
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Regeneron, A Leading U.S. Biotechnology Company, to Acquire 23andMe in Court-Supervised Sale
From 23andMe, Inc.
Via GlobeNewswire
3 Stocks That Will Profit From Trump's Drug Price Cut
Via Benzinga
Topics Government
Exposures Political
75th Annual Regeneron International Science and Engineering Fair Awards Teen Scientists from Around the World More Than $9 Million in 2025 Competition
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
1 Nasdaq 100 Stock with Exciting Potential and 2 to Think Twice About
Via StockStory
Regeneron Prevails over Amgen in Antitrust PCSK9 Lawsuit Protecting Biotech Innovation and Patient Access to Life-Saving Treatments
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Big Dippers: 3 Stocks Near 1-Year Lows That Could Surge in 2025
Via MarketBeat
Topics Government World Trade
Exposures Political Tariff
Sanofi To Navigate Tariff Impact With $20 Billion In Spending Through 2030
Via Benzinga
Beyond The Numbers: 16 Analysts Discuss Regeneron Pharmaceuticals Stock
Via Benzinga
Only Half Of S&P 500 Stocks Joined The Tariff-Relief Rally: Time To Buy The Laggards?
Via Benzinga
Topics Stocks
Exposures US Equities
This PVH Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday
Via Benzinga
Best Biotech Stocks to Buy in 2025
Via MarketBeat
Topics ETFs Economy Government
Exposures COVID-19 Interest Rates Political
REGN Q1 Earnings Call: Pipeline Progress and EYLEA Headwinds Dominate Discussion
Via StockStory

Frequently Asked Questions

Is Regeneron Pharmaceuticals publicly traded?
Yes, Regeneron Pharmaceuticals is publicly traded.
What exchange does Regeneron Pharmaceuticals trade on?
Regeneron Pharmaceuticals trades on the Nasdaq Stock Market
What is the ticker symbol for Regeneron Pharmaceuticals?
The ticker symbol for Regeneron Pharmaceuticals is REGN on the Nasdaq Stock Market
What is the current price of Regeneron Pharmaceuticals?
The current price of Regeneron Pharmaceuticals is 605.39
When was Regeneron Pharmaceuticals last traded?
The last trade of Regeneron Pharmaceuticals was at 05/29/25 04:00 PM ET
What is the market capitalization of Regeneron Pharmaceuticals?
The market capitalization of Regeneron Pharmaceuticals is 55.56B
How many shares of Regeneron Pharmaceuticals are outstanding?
Regeneron Pharmaceuticals has 56B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.